Literature DB >> 3042605

Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.

S A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3042605

Source DB:  PubMed          Journal:  Important Adv Oncol        ISSN： 0883-5896


× No keyword cloud information.
  12 in total

1.  Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.

Authors:  J Walewski; E Paietta; J Dutcher; P H Wiernik
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 2.  Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.

Authors:  Richard D Lopez
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Interleukin-2 therapy for human cancer.

Authors:  Q G van Hoesel
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.

Authors:  P Zanovello; A Rosato; V Bronte; S Mandruzzato; V Cerundolo; D Collavo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.

Authors:  S C Helfand; S A Soergel; P S MacWilliams; J A Hank; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

6.  Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.

Authors:  N Rajaram; R J Tatake; S H Advani; S L Naik; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 7.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

8.  Malignant melanoma in a black child: predisposing precursors and management.

Authors:  Olanrewaju T Adedoyin; Abdul-Wahab B R Johnson; Ayodele I Ojuawo; Enoch A O Afolayan; Kayode A Adeniji
Journal:  J Natl Med Assoc       Date:  2004-10       Impact factor: 1.798

9.  Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.

Authors:  E J West; K J Scott; V A Jennings; A A Melcher
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

10.  Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.

Authors:  G Facendola; M C Locatelli; G Pizzocaro; L Piva; C Pegoraro; E B Pallavicini; A Signaroldi; M Meregalli; F Lombardi; G D Beretta
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.